Interferon-mediated in vivo induction of β2-microglobulin on small-cell lung cancers and mid-gut carcinoids

Keiko Funa, Adi F. Gazdar, Karin Mattson, Aili Niiranen, Ari Koivuniemi, Kjell Öberg, Erik Wilander, Austin Doyle, R. Ilona Linnoila

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Selected neuroendocrine tumors, such as small cell lung cancer (SCLC), and neuroblastoma express markedly diminished class I major histocompatibility complex (MHC) antigens (HLA framework and β2-microglobulin, β2m). Another neuroendocrine tumor, mid-gut carcinoid, also expresses reduced β2m antigen as demonstrated herein. Antigen expression is greatly enhanced on SCLC cell lines by in vitro exposure to interferon (IFN). To determine whether IFN mediates similar effects in vivo, we examined by immunoperoxidase staining β2m expression in paraffin-embedded tumor tissue sections obtained from 4 SCLC and 7 mid-gut carcinoid patients before and after receiving partially purified human leukocyte IFN-α therapy. Before IFN treatment, 3 4 SCLC tumors and 5 7 mid-gut carcinoids did not express β2m. By contrast, all tumors showed considerable expression of β2m after IFN therapy. Induction of class I antigens on tumor cells deficient in such expression may be one mechanism by which IFN exerts antitumor effects. We believe this is the first report of in vivo induction of class I MHC antigens in epithelial tumor cells in humans.

Original languageEnglish (US)
Pages (from-to)159-164
Number of pages6
JournalClinical Immunology and Immunopathology
Volume41
Issue number1
DOIs
StatePublished - 1986

Fingerprint

Small Cell Lung Carcinoma
Carcinoid Tumor
Interferons
Histocompatibility Antigens Class I
Neuroendocrine Tumors
Neoplasms
Major Histocompatibility Complex
Antigens
Neuroblastoma
Interferon-alpha
Paraffin
Therapeutics
Epithelial Cells
Staining and Labeling
Cell Line

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Funa, K., Gazdar, A. F., Mattson, K., Niiranen, A., Koivuniemi, A., Öberg, K., ... Ilona Linnoila, R. (1986). Interferon-mediated in vivo induction of β2-microglobulin on small-cell lung cancers and mid-gut carcinoids. Clinical Immunology and Immunopathology, 41(1), 159-164. https://doi.org/10.1016/0090-1229(86)90060-7

Interferon-mediated in vivo induction of β2-microglobulin on small-cell lung cancers and mid-gut carcinoids. / Funa, Keiko; Gazdar, Adi F.; Mattson, Karin; Niiranen, Aili; Koivuniemi, Ari; Öberg, Kjell; Wilander, Erik; Doyle, Austin; Ilona Linnoila, R.

In: Clinical Immunology and Immunopathology, Vol. 41, No. 1, 1986, p. 159-164.

Research output: Contribution to journalArticle

Funa, K, Gazdar, AF, Mattson, K, Niiranen, A, Koivuniemi, A, Öberg, K, Wilander, E, Doyle, A & Ilona Linnoila, R 1986, 'Interferon-mediated in vivo induction of β2-microglobulin on small-cell lung cancers and mid-gut carcinoids', Clinical Immunology and Immunopathology, vol. 41, no. 1, pp. 159-164. https://doi.org/10.1016/0090-1229(86)90060-7
Funa, Keiko ; Gazdar, Adi F. ; Mattson, Karin ; Niiranen, Aili ; Koivuniemi, Ari ; Öberg, Kjell ; Wilander, Erik ; Doyle, Austin ; Ilona Linnoila, R. / Interferon-mediated in vivo induction of β2-microglobulin on small-cell lung cancers and mid-gut carcinoids. In: Clinical Immunology and Immunopathology. 1986 ; Vol. 41, No. 1. pp. 159-164.
@article{c8151cd04cad439993b1885b22f5f924,
title = "Interferon-mediated in vivo induction of β2-microglobulin on small-cell lung cancers and mid-gut carcinoids",
abstract = "Selected neuroendocrine tumors, such as small cell lung cancer (SCLC), and neuroblastoma express markedly diminished class I major histocompatibility complex (MHC) antigens (HLA framework and β2-microglobulin, β2m). Another neuroendocrine tumor, mid-gut carcinoid, also expresses reduced β2m antigen as demonstrated herein. Antigen expression is greatly enhanced on SCLC cell lines by in vitro exposure to interferon (IFN). To determine whether IFN mediates similar effects in vivo, we examined by immunoperoxidase staining β2m expression in paraffin-embedded tumor tissue sections obtained from 4 SCLC and 7 mid-gut carcinoid patients before and after receiving partially purified human leukocyte IFN-α therapy. Before IFN treatment, 3 4 SCLC tumors and 5 7 mid-gut carcinoids did not express β2m. By contrast, all tumors showed considerable expression of β2m after IFN therapy. Induction of class I antigens on tumor cells deficient in such expression may be one mechanism by which IFN exerts antitumor effects. We believe this is the first report of in vivo induction of class I MHC antigens in epithelial tumor cells in humans.",
author = "Keiko Funa and Gazdar, {Adi F.} and Karin Mattson and Aili Niiranen and Ari Koivuniemi and Kjell {\"O}berg and Erik Wilander and Austin Doyle and {Ilona Linnoila}, R.",
year = "1986",
doi = "10.1016/0090-1229(86)90060-7",
language = "English (US)",
volume = "41",
pages = "159--164",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Interferon-mediated in vivo induction of β2-microglobulin on small-cell lung cancers and mid-gut carcinoids

AU - Funa, Keiko

AU - Gazdar, Adi F.

AU - Mattson, Karin

AU - Niiranen, Aili

AU - Koivuniemi, Ari

AU - Öberg, Kjell

AU - Wilander, Erik

AU - Doyle, Austin

AU - Ilona Linnoila, R.

PY - 1986

Y1 - 1986

N2 - Selected neuroendocrine tumors, such as small cell lung cancer (SCLC), and neuroblastoma express markedly diminished class I major histocompatibility complex (MHC) antigens (HLA framework and β2-microglobulin, β2m). Another neuroendocrine tumor, mid-gut carcinoid, also expresses reduced β2m antigen as demonstrated herein. Antigen expression is greatly enhanced on SCLC cell lines by in vitro exposure to interferon (IFN). To determine whether IFN mediates similar effects in vivo, we examined by immunoperoxidase staining β2m expression in paraffin-embedded tumor tissue sections obtained from 4 SCLC and 7 mid-gut carcinoid patients before and after receiving partially purified human leukocyte IFN-α therapy. Before IFN treatment, 3 4 SCLC tumors and 5 7 mid-gut carcinoids did not express β2m. By contrast, all tumors showed considerable expression of β2m after IFN therapy. Induction of class I antigens on tumor cells deficient in such expression may be one mechanism by which IFN exerts antitumor effects. We believe this is the first report of in vivo induction of class I MHC antigens in epithelial tumor cells in humans.

AB - Selected neuroendocrine tumors, such as small cell lung cancer (SCLC), and neuroblastoma express markedly diminished class I major histocompatibility complex (MHC) antigens (HLA framework and β2-microglobulin, β2m). Another neuroendocrine tumor, mid-gut carcinoid, also expresses reduced β2m antigen as demonstrated herein. Antigen expression is greatly enhanced on SCLC cell lines by in vitro exposure to interferon (IFN). To determine whether IFN mediates similar effects in vivo, we examined by immunoperoxidase staining β2m expression in paraffin-embedded tumor tissue sections obtained from 4 SCLC and 7 mid-gut carcinoid patients before and after receiving partially purified human leukocyte IFN-α therapy. Before IFN treatment, 3 4 SCLC tumors and 5 7 mid-gut carcinoids did not express β2m. By contrast, all tumors showed considerable expression of β2m after IFN therapy. Induction of class I antigens on tumor cells deficient in such expression may be one mechanism by which IFN exerts antitumor effects. We believe this is the first report of in vivo induction of class I MHC antigens in epithelial tumor cells in humans.

UR - http://www.scopus.com/inward/record.url?scp=0022483321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022483321&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(86)90060-7

DO - 10.1016/0090-1229(86)90060-7

M3 - Article

C2 - 3017623

AN - SCOPUS:0022483321

VL - 41

SP - 159

EP - 164

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -